Ybrain, a company specializing in mental health therapeutics, said on Tuesday that it signed a joint promotion contract with Chong Kun Dang Holdings for MINDD STIM, a prescription depression electroceutical for at-home use.

Under the agreement, Chong Kun Dang will exclusively supply and sell Ybrain's MINDD STIM to domestic psychiatrists. The company will carry out academic activities and product education for the smooth sales of MINDD STIM.

In clinical trials conducted in Korea in 2020, the remission rate of depressive symptoms was 62.8 percent, which was 12.8 percent more compared to existing antidepressants when applying MIND STIMM alone for 30 minutes every day for six weeks, according to Ybrain.

Ybrain will be in charge of installing products, customer inquiries, and claims for MINDD STIM sold by Chong Kun Dang, as well as consumer response and defect repair.

Accordingly, MINDD STIM, which the company says the world's first electronic drug for depression, will be distributed in Korea through Chong Kun Dang's network.

Chong Kun Dang also agreed to actively cooperate with Ybrain’s Blue Band campaign to promote early diagnosis and treatment of depression in Korea. The campaign is conducted in collaboration with the Korean Neuropsychiatric Association to raise awareness of depression.

"Joint promotion with Chong Kun-dang will initiate MINDD STIM’s full-fledged distribution across Korea and help create an atmosphere for earlier diagnosis and treatment of mental health diseases,” said Ybrain CEO Lee Ki-won.

“MINDD STIM has been approved for in-hospital use through confirmatory clinical trials for the first time in the world,” said Chong Kun-dang CEO Kim Young-joo. “It is expected to be a treatment option with high satisfaction in the field of neuroscience digital healthcare.”